Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arbutus Biopharma Corporation (ABUS)
NASDAQ:ABUS
Arbutus Biopharma (ABUS) Stock Price & Analysis
1,184 Followers
ABUS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.69 - $3.64
Previous Close$3.12
Volume511.83K
Average Volume (3M)1.38M
Market Cap
$588.80M
Enterprise Value$461.24M
Total Cash (Recent Filing)$129.24M
Total Debt (Recent Filing)$1.68M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Aug 01, 2024EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding188,717,409
10 Day Avg. Volume1,047,106
30 Day Avg. Volume1,375,925
Standard Deviation0.27
R-Squared0.15
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)5.43
Price to Sales (P/S)375.71
Price to Cash Flow (P/CF)-8.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue37.74
Enterprise Value/Gross Profit25.43
Enterprise Value/Ebitda-6.25
Forecast
1Y Price Target
$4.25Price Target Upside36.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Arbutus Biopharma News
PremiumCompany Announcements
Arbutus Reports Promising Hepatitis B Trial Results
PremiumCompany Announcements
Arbutus Biopharma’s Promising HBV Treatment Data
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ABUS FAQ
What was Arbutus Biopharma Corporation’s price range in the past 12 months?
Arbutus Biopharma Corporation lowest stock price was $1.69 and its highest was $3.64 in the past 12 months.
What is Arbutus Biopharma Corporation’s market cap?
Currently, no data Available
When is Arbutus Biopharma Corporation’s upcoming earnings report date?
Arbutus Biopharma Corporation’s upcoming earnings report date is Aug 01, 2024 which is in 30 days.
How were Arbutus Biopharma Corporation’s earnings last quarter?
Arbutus Biopharma Corporation released its earnings results on May 02, 2024. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.11 by $0.01.
Is Arbutus Biopharma Corporation overvalued?
According to Wall Street analysts Arbutus Biopharma Corporation’s price is currently Undervalued.
Does Arbutus Biopharma Corporation pay dividends?
Arbutus Biopharma Corporation does not currently pay dividends.
What is Arbutus Biopharma Corporation’s EPS estimate?
Arbutus Biopharma Corporation’s EPS estimate is -$0.1.
How many shares outstanding does Arbutus Biopharma Corporation have?
Arbutus Biopharma Corporation has 188,717,400 shares outstanding.
What happened to Arbutus Biopharma Corporation’s price movement after its last earnings report?
Arbutus Biopharma Corporation reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.11. Following the earnings report the stock price went down -0.372%.
Which hedge fund is a major shareholder of Arbutus Biopharma Corporation?
Among the largest hedge funds holding Arbutus Biopharma Corporation’s share is Woodline Partners LP. It holds Arbutus Biopharma Corporation’s shares valued at 11M.
---
Arbutus Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.25 (36.22% Upside)
$4.25 (36.22% Upside)
Hedge Fund Trend
Decreased
By 275.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.65%
12-Months-Change
Fundamentals
Return on Equity
-57.54%
Trailing 12-Months
Asset Growth
-21.41%
Trailing 12-Months
Company Description
Arbutus Biopharma Corporation
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
---
ABUS Earnings Call
Q4 2024
0:00 / 0:00
---
ABUS Stock 12 Month Forecast
Average Price Target
$4.25
▲(36.22% Upside)
Technical Analysis
Best Analysts Covering ABUS
1 Year
1 Year Success Rate
12/36 ratings generated profit
1 Year Average Return
-15.06%
reiterated a buy rating 27 days ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -15.06% per trade.
---